Key terms
About PHAT
Phathom Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel treatments for gastrointestinal diseases. The company was founded by Tadataka Yamada, David Socks, Azmi Nabulsi, Aditya Kohli, and Roger Ulrich on January 9, 2018 and is headquartered in Florham Park, NJ.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest PHAT news
Today
9:16am ET
Craig-Hallum Remains a Buy on Phathom Pharmaceuticals (PHAT)
Today
6:40am ET
Wall Street Analysts Are Bullish on Top Healthcare Picks
Yesterday
12:20pm ET
Analysts Offer Insights on Healthcare Companies: Phathom Pharmaceuticals (PHAT), ACELYRIN, INC. (SLRN) and Moderna (MRNA)
Yesterday
8:08am ET
Phathom Pharmaceuticals sees cash runway through 2026
Yesterday
8:07am ET
Phathom Pharmaceuticals reports Q1 EPS ($1.42), consensus ($1.31)
May 06
9:07am ET
Phathom Pharmaceuticals (PHAT) Receives a Buy from Craig-Hallum
May 03
9:05am ET
Buy Rating Affirmed for Phathom Pharmaceuticals on V oquezna’s Promising Market Trajectory
May 02
4:13pm ET
Phathom Pharmaceuticals initiated with a Buy at Stifel
Apr 26
8:25am ET
Buy Rating Justified by Strong Market Acceptance of Phathom Pharmaceuticals’ V oquezna
Apr 19
9:25am ET
Buy Rating Affirmed for Phathom Pharmaceuticals Amid Strong Uptake of V oquezna
Apr 05
9:35am ET
Optimistic Outlook for Phathom Pharmaceuticals’ Voquezna Despite Prescription Data Fluctuations
Apr 01
6:50am ET
Analysts Offer Insights on Healthcare Companies: Achieve Life Sciences (ACHV) and Phathom Pharmaceuticals (PHAT)
Mar 25
7:38am ET
Siga Technologies appoints Larry Miller as general counsel
Mar 22
9:35am ET
Positive Prescription Trends and Resilience Prompt Buy Rating for Phathom Pharmaceuticals
Mar 15
10:30am ET
Analysts’ Top Healthcare Picks: Longboard Pharmaceuticals (LBPH), Phathom Pharmaceuticals (PHAT)
Mar 09
9:55am ET
Short Report: Bearish positions reduced after contrasting C3.ai and Figs results
Mar 08
8:46am ET
Craig-Hallum Issues a Buy Rating on Phathom Pharmaceuticals (PHAT)
Mar 08
6:27am ET
Phathom Pharmaceuticals’ Voquezna Shows Promising Market Traction and Growth Potential: A Buy Rating Analysis
Mar 07
5:35pm ET
Maintaining Neutral on Phathom Pharmaceuticals Amid Voquezna Launch Uncertainties
Mar 07
12:25pm ET
Buy Rating on Phathom Pharmaceuticals Amid Strong Voquezna Launch Demand
Mar 07
8:03am ET
Phathom Pharmaceuticals reports Q4 EPS ($1.39), consensus ($1.08)
Mar 01
9:30am ET
Analysts Offer Insights on Healthcare Companies: Phathom Pharmaceuticals (PHAT) and Pacira Pharmaceuticals (PCRX)
Feb 23
9:35am ET
Strong Market Uptake of Phathom Pharmaceuticals’ V oquezna Spurs Buy Rating
Feb 22
10:59am ET
Biotech Alert: Searches spiking for these stocks today
Feb 16
9:55am ET
Buy Rating Justified: Voquezna’s Strong Market Launch and Growth Potential
Feb 13
8:22am ET
Phathom Pharmaceuticals’ VOQUEZNA Added to Express Scripts Formularies
No recent press releases are available for PHAT
PHAT Financials
Key terms
Ad Feedback
PHAT Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
PHAT Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
